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Prescription Drug Prices Will Drive Health Insurance 
Premium Increases in 2017
Jeff Rubleski, MBA, Director, Sales Strategy, Blue Cross Blue Shield of Michigan
Adjunct Faculty Member, Seidman School of Business
The top driver of rising health 
insurance premiums for 2017 is 
the cost of prescription drugs. 
Medical inflation for health  
insurance premiums is  
measured by a term referred  
to as “trend.” In 2017, the  
prescription drug trend is  
projected to be 11.6 percent, up 
from 11.3 percent in 20161. The 
annual prescription drug trend 
is alarming, considering that it 
is almost a 7x multiple of gen-
eral inflation in our economy,  
represented by the Consumer 
Price Index (CPI).2 Based on a host of factors, including 
individuals being treated at an increased rate for chronic 
conditions and diseases, aggressive pharmaceutical price 
increase policies for existing drugs and the introduction 
of new and very expensive drug therapies, it appears that 
annual drug price trend increases will continue at a pace that 
widely exceeds the CPI for years to come.
The single largest factor behind the year-over-year increase  
in prescription drug trend involves what are labeled as  
specialty drugs, which treat complex conditions such as  
cancer, hepatitis C, arthritis, multiple sclerosis, and a multitude 
of other chronic and debilitating medical conditions and  
diseases. Advances in complex genetic research over the past 
decade have served as the catalyst for the development of 
these drugs. Pharmaceutical companies collectively spend  
billions of dollars to develop specialty drugs that have a high 
risk of failure, as most specialty drugs do not pass stringent 
Food and Drug Administration (FDA) testing that is required 
before prescription drugs are approved to go to market. 
However, the relatively few specialty drugs that do pass FDA 
testing once introduced to consumers can produce “lottery 
ticket-like” revenues and profits for pharmaceutical  
companies. To put into context the cost impact of specialty 
drugs, consider that they account for less than 1 percent of  
all prescribed medications, yet they account for about  
35 percent of total prescription drug cost trends for 2017!3
For pharmaceutical companies, the high risk and correspondingly 
high return nature of specialty drug development make them a 
top priority for market introduction. It appears that this trend will 
continue to accelerate in future years with scores of promising  
new specialty drugs in the pipelines of many pharmaceutical 
companies. All of this translates into continued development of 
new specialty drugs that can treat and cure debilitating and even 
terminal conditions, yet at a cost that is increasingly becoming 
a financial burden for both consumers who use and pay more 
to acquire the medications and businesses that pay most of the 
cost of prescription drugs through company-sponsored health 
insurance programs. In a 2016 health care tracking poll, The Kaiser 
Family Foundation discovered that one in four people in the 
United States have trouble paying for their medication.4 Expect 
affordability issues to increase in future years as businesses and 
consumers are forced to absorb the increasing cost of the  
ever-growing list of specialty drugs. 
Specialty Drugs—the “Silver Lining”  
for Consumers
Specialty drugs produce powerful life-enhancing and  
sometimes life-saving results for consumers who need them. 
They can deliver rates of cure from disease and long-term 
relief from chronic health conditions that just a decade ago 
would have been impossible to treat with traditional drug 
therapies. For example, hepatitis C is a terrible disease that 
afflicts an estimated 3.5 million Americans. In 2014, the Centers 
for Disease Control (CDC) documented 19,659 deaths from 
hepatitis C, making it the leading cause of death of Americans 
from infectious disease.5 In 2013 and 2014 the specialty drugs 
Sovaldi and Harvoni received FDA approval as a cure for  
hepatitis C. These drugs provide a cure of hepatitis C for over 
90 percent of the patients who receive treatment. But the cost 
of both drugs is staggering and out of financial reach for those 
who do not have some form of insurance coverage or external 
subsidy. The average cost for Harvoni is $94,500 for a 12 week 
treatment program, resulting in a cost of over $1,100 per pill! 
(Note that a 12 week treatment of Sovaldi is about $84,000 or 
around $1,000 per pill.)6 These drugs are often combined with 
other drug therapies when treating hepatitis C, resulting in a 
total price tag that often exceeds $100,000 to treat and cure 
hepatitis C.
Naturally health insurance premiums are directly impacted  
by rising prescription drug costs. Figure 1 shows the  
breakdown of key components that factor into the pricing  
of health insurance premiums.7 Note that prescription drugs 
represent the largest component of the total premium  
expenditure for health insurance, accounting for 29% of  
total health insurance premiums. 
Just a few years ago, prescription drug spending accounted 
for less than 20% of the total health insurance premium  
1 Segal 2017 Health Plan Cost Trend Survey, September 27, 2016, www.segalco.com.
2 Bureau of Labor Statistics, September 2016 CPI Detailed Report, www.bls.gov. 
3 Segal 2017 Health Plan Cost Trend Survey, September 27, 2016, www.segalco.com.
4 Kaiser Family Foundation Health Tracking Poll, September 2016, www.kff.org.
5 Centers for Disease Control, Clinical Infectious Diseases online publication, May 4, 2016.
6 Hepatitis C Society, 2016. 
7 Blue Cross Blue Shield of Michigan Book of Business Analysis 2015.
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expenditure, so rapidly growing prescription drug spending is  
a concern for both employers who continue to pay for a  
majority of health insurance premiums and for employees, who 
likely are now paying much more in out-of-pocket expenses to 
obtain necessary pharmacy benefits than they did just a couple 
of years ago. 
Four Actionable Strategies for Controlling 
Rising Prescription Drug Costs 
With drug costs continuing to rise, there are a number of  
strategies businesses can take to control cost and to  
encourage employees and their covered family members to 
utilize the lowest priced prescription drug therapy to treat a 
diagnosed condition. Here are four strategies to consider when 
managing the rising cost of prescription drugs:
1.  Consider adopting or modifying any existing multi-tier  
prescription drug benefit. Insurance carriers and pharmacy 
benefit managers now offer a variety of prescription drug 
tiers in an effort to direct covered members to the lowest 
cost drug therapy. The most common multi-tier formats offer 
4 to 6 tiers, with each tier representing a higher out-of-pocket 
drug cost for the member. Specialty drugs are represented in 
the last tier and carry the highest out-of-pocket cost. Be sure 
to understand the likely wide spectrum of multi-tier options 
available, including deductibles linked to prescription drug 
spending, fixed copayment, and coinsurance payments per 
drug tier. Making thoughtful adjustments to your pharmacy 
benefit can save significant premium dollars. 
2.  Educate employees on the cost of prescription drugs 
through targeted communications. With more employers 
introducing multi-tier prescription drug benefits that shift 
cost to members for higher tier drug use, it is important for 
your employees and their covered family members to  
understand why the sometimes confusing multi-tier approach  
is necessary and how they can lower their out-of-pocket 
costs by asking their health care provider to prescribe  
generics whenever possible. Your insurance company or 
pharmacy benefit manager should have a number of turn-key 
communications available to help you to communicate with 
employees and covered family members. 
3.  Work with a good health benefits agent or consultant to  
help you to navigate your prescription drug options and to 
recommend options that make the most sense for your  
organization. A good agent should present a number of 
viable prescription drug options for consideration and should 
also provide guidance on how to communicate coverage 
changes to employees and family members. Also seek the 
input of your current insurance carrier or current pharmacy 
benefit manager for their insight on what your organization 
can do to control rising costs while still providing a solid  
prescription drug benefit for your employees and their  
covered family members. 
4.  If your group is self insured or is experience rated for medical 
and prescription drug claims (typically if your group insures 
more than 50 employees, your plan will be experience rated), 
consider purchasing stop-loss coverage for prescription drug 
costs that exceed a designated level at the employee  
contract level (referred to as specific stop-loss coverage) and 
for the total amount of group pharmacy expenses (referred 
to as aggregate stop-loss coverage). For many companies, 
this extra form of risk reduction stop-loss coverage will be a 
good decision, as specialty pharmacy costs can exceed over 
$100,000 for just one treatment regimen.
The cost of prescription drugs will continue to rise, and  
understanding the factors that are driving these ongoing 
increases will allow you to take proactive steps to keep  
pharmaceutical premium increases in line with your health 
insurance budget. The decisions you’ll need to make are by no 
means easy, but will be necessary to keep health insurance a 
viable option for your organization. Commit to understanding 
the factors driving your organization’s pharmacy drug costs 
and take advantage of plan design and strategies to keep the 
rising cost of your pharmacy benefits in check. 
Figure 1: Medical Service Costs  
As A Percentage of Total Health  
Insurance Premiums
Source: Blue Cross Blue Shield of Michigan 2015 Book of Business Analysis
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